GlassScriptPhysician profile
Brian J Deegan
NPI 1639513757
$650.45
in general payments reported to CMS, 2019-2025
15 companies · $33.63 in 2025
The $33.63 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.76 · 2020: $20.19 · 2021: $218 · 2022: $37.97 · 2023: $156 · 2024: $111 · 2025: $33.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainlab, INC. | $189.24 | 2023-2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning, Image Guided Surgical Device |
| Genzyme Corporation | $110.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $83.85 | 2021-2025 | |
| Foundation Medicine, INC. | $71.43 | 2019-2021 | |
| Pfizer INC. | $32.01 | 2021-2023 | |
| Novocure INC. | $27.77 | 2021 | |
| Emmaus Medical, INC. | $18.31 | 2019 | |
| Boston Scientific Corporation | $17.07 | 2023 | Spaceoar Vue System - 10ml |
| Ambu INC. | $15.66 | 2021 | |
| Spectrum Pharmaceuticals INC. | $15.41 | 2025 | Rolvedon |
| Amgen INC. | $14.71 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.14 | 2019 | |
| Incyte Corporation | $14.08 | 2023 | Jakafi |
| Genentech USA, INC. | $13.65 | 2022 | |
| Array Biopharma INC | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Deegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.